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1. Introduction
  Preliminary studies have found that, colorectal cancer 
is characterized by bloating, poor appetite, constipation, 
diarrhea and other spleen deficiency syndromes. It is 
proposed that the use of Yiqi Jianpi decoction combined 
with anticancer herbs is effective in treatment of colorectal 
cancer. Spleen deficiency related proteins and signaling 
pathways is helpful in further study on mechanism of Yiqi 
Jianpi decoction. In this study, we explored the molecular 
mechanisms about anticancer effects of Yiqi Jianpi 
decoction[1].
2. Materials and methods
2.1. Cell lines and experimental animals
  HT29, a human colon cancer cell line, was purchased 
from Cell Biology Laboratory of Zhengzhou University, 
Zhengzhou, Henan Province, China. Forty nude mice and 
forage, of specific pathogen free grade, were purchased 
from Experimental Animal Center of Zhengzhou University, 
Zhengzhou, Henan Province, China. Sterile gauze pad was 
also prepared.
2.2. Drugs, reagents and instruments
  Yiqi Jianpi decoction included radix pseudostellariae, 
poria, rhizoma atractylodis macrocephalae, radix 
glycytthizae, rhizoma pinelliae, pericarpium citri 
reticulatae, radix aucklandiae, and fructrs amomi, total 400 g.
Anticancer herbs contained pseudobulbus cremastrae 
seu pleiones, rhizoma smilacis glabrae, bulbus fritillariae 
thunbergii, and hedyotic diffusa, total 240 g. All were 
provided by the Bureau of Drugs, Department of Outpatient, 
Traditional Chinese Medicine Hospital of Henan Province, 
China. 200 mL drug solution was obtained through 
conventional boiling and then was concentrated to 85 mL, 
thus the concentration of the extracts was 2.2 g/mL. The 
extraction was packaged at 10 mL/bottle, deactivated at 
high pressure (0.1-0.15 KPa) for 15 min, and stored at 4℃.
  Fetal bovine serum and phosphate buffer solution were 
purchased from Tianjin Haoyang Biological Manufacture 
Co., Ltd., Tianjin, China. 
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  Centrifuge machine, micro-medical imaging systems, 
microplate reader, plate washer, fluorescence microscopy, 
refrigerator, carbon dioxide incubator, inverted microscope, 
electric heat incubator, microscope, Beckman centrifuge 
tube, and low speed centrifuge machine were used in this 
study.
2.3. Methods
2.3.1. In vitro culture of HT29 cells
  HT29 cell lines were cultured with RPMI 1640 medium 
containing 10% fetal calf serum in an incubator at 37 ℃, 
5% CO2, and saturated humidity. The adherent cells at 
logarithmic growth phase were digested and prepared into 
1×104/mL suspension with fresh medium. Subsequently 
100 毺L cell suspension was added to each hole in the 96-
well culture plate and incubated for 24 h at 37 ℃, 5% CO2. 
Afterwards the culture medium was replenished to serum-
free medium, and the test serum was added to each hole 
(10 毺L/hole), three holes at the same concentration. The 
control hole was added with 10 毺L normal serum and the 
blank hole was added with 100 毺L culture medium. All the 
cells were cultured for 72 h, and 100 毺L MTT solution was 
added to each hole (5 mg/mL) and the cells were incubated 
for additional 4 h, each well was added with 100 毺L lysate 
and stayed overnight. The absorbance value at 570 nm was 
measured with a automated microplate reader. T189 cells 
at logarithmic phase were obtained and prepared into cell 
suspension at 5.0 × 104 cells/mL.
2.3.2. Establishment of xenograft model of HT29 colorectal 
cancer cells in nude mice
  HT29 cells at logarithmic growth phase were adjusted to 
1×107/mL and then 0.1 mL suspension was transplanted into 
the armpit of mice, 1×107 cells per mouse. The operations 
were performed under sterile conditions and tumor growth 
was observed daily. The tumor model was defined a success 
upon the appearance of 0.8 cm diameter of tumor nodule and 
hard tissue texture at 15 days after inoculation.
2.3.3. Grouping and treatment
  The mice were divided into four groups: normal group, 
model group, Yiqi Jianpi treatment group, and Yiqi Jianpi 
plus anticancer treatment group. There were ten mice in 
each group. Normal group and model group were given 
intragastrical administration of saline for 14 days, while two 
treatment groups received Yiqi Jianpi decoction and Yiqi 
Jianpi decoction plus anticancer herbs respectively, for 14 
days.
2.3.4. Index detection
  The animal’s diet, activity, fur, color, weight, and sweating 
were observed. The changes of animal’s liver, kidney, and 
spleen after treatment were also detected. All mice were 
weighed.
  At the end of the experiments, nude mice were sacrificed 
and the tumors were isolated, fixed in 10% formalin for 24 h, 
embedded in paraffin, and sliced. The obtained slices were 
stained with hematoxylin-eosin, and pathological changes 
of colorectal cancer tissue were observed under light 
microscopy.
  Protein kinase C (PKC) in spleen was detected using 
western blot analysis[2].
  The colorectal cancer tissue in nude mice was incubated 
with protease K (20 mg/L) at 37 ℃ for 15-30 min after 
paraffin-embedding, dewaxing and hydration. Cell apoptosis 
was determined according to the instructions of TUNEL assay 
kit. In brief, the tissue was incubated with 50 毺L reaction 
solution in a wet box at 37 ℃ in the dark, for 60 minutes, and 
then observed under a fluorescence microscope. Each slice 
was observed through more than five high-power fields, and 
the percentage of apoptotic cells was calculated. Percentage 
= number of positive cells / number of total cells × 100%[3].
The expression of epidermal growth factor (EGF) and 
vascular endothelial growth factor (VEGF) were detected 
according to the instructions of EGF and VEGF kits.
3. Results
3.1. PKC expression in the mouse spleen
  There was significant difference in expression of PKC 
among different groups after treatment. As shown in Figure 
1, the expression of PKC in spleen was the highest in normal 
group, then Yiqi Jianpi plus anticancer treatment group, 
Yiqi Jianpi treatment group and model group. Compared 
with the normal group, the expression of PKC was decreased 
in other three groups (P<0.01). Compared with the model 
group, the expression of PKC was significantly increased 
in normal group and Yiqi Jianpi plus anticancer treatment 
group (P<0.01), and was slightly increased in Yiqi Jianpi 
treatment group, with significant difference (P<0.05).
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Figure 1. PKC expression in the spleen of rat from different groups.
PKC molecular weight: 5.8 kDa; 毬-actin molecular weight: 42 kDa.
3.2. Detection of cell apoptosis
  The cell apoptosis was detected with TUNEL assay after 
treatment. As shown in Table 2 and Figure 2, the number of 
apoptotic cells showed significant differences in Yiqi Jianpi 
plus anticancer treatment group and Yiqi Jianpi treatment 
group compared with the model group (P<0.01). In addition, 
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the number of apoptotic cells in Yiqi Jianpi plus anticancer 
treatment group was significantly higher than that in Yiqi 
Jianpi treatment group (P<0.01).
3.3. EGF and VEGF expression
  After the apoptosis of tumor cells was detected, tumor 
tissue in model group, Yiqi Jianpi treatment group and 
Yiqi Jianpi plus anticancer treatment group was harvested 
to determine the EGF and VEGF expression. As shown in 
Table 1 and Figure 3, the EGF and VEGF expression reached 
a peak in the model group, which was significantly higher 
than that in Yiqi Jianpi treatment group and Yiqi Jianpi plus 
anticancer treatment group (P<0.01). In addition, Yiqi Jianpi 
treatment group showed significantly higher expression 
levels than Yiqi Jianpi plus anticancer treatment group 
(P<0.05).
m
od
el
 g
ro
up
no
rm
al
 g
ro
up
Y
iq
i J
ia
np
i p
lu
s 
an
tic
an
ce
r 
tr
ea
tm
en
t g
ro
up
m
od
el
 g
ro
up
no
rm
al
 g
ro
up
Y
iq
i J
ia
np
i p
lu
s 
an
tic
an
ce
r 
tr
ea
tm
en
t g
ro
up
5.8 kDa 42 kDa
 
Figure 3. EGF expression in HT29 tumor cells.
EGF molecular weight: 5.8 kDa; 毬-actin molecular weight: 42 kDa.
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Figure 4. VEGF expression in HT29 tumor cells. 
VEGF factor molecular weight: 23 kDa; 毬-actin molecular weight: 
42 kDa.
4. Discussion
  Changes in PKC reflect the variation in the spleen and are 
positively correlated with splenic functions. Once the tumor 
forms, spleen PKC content sharply decreases, highlighting 
the impact of tumor on the function of the spleen[4,5]. The 
present study found that the tumor had an apparent impact 
on the spleen and adverse effects on PKC, which underlines 
the tumor’s damage on splenic function. After treatment of 
Yiqi Jianpi plus anticancer decoction, PKC expression began 
to increase. This indicates that the tumor-caused damage 
was decreased slightly. Although Yiqi Jianpi plus anticancer 
treatment showed an obvious clinical efficacy, the level was 
still lower than normal levels[6-9].
Table 1 
PKC expression among groups detected by western blot analysis.
Group PKC HT29 EGF expression VEGF expression
Normal group 0.567依0.011# - - -
Model group 0.422依0.008* 0.60依0.70 0.574依0.020  0.596依0.014  
Yiqi Jianpi treatment group    0.442依0.019 ##*  3.50依1.08*  0.506依0.023*  0.533依0.016* 
Yiqi Jianpi plus anticancer treatment group   0.480依0.014 #*  8.70依1.34*#   0.368依0.021*#   0.419依0.012*#
Note: #P<0.01, ##P<0.05, vs. model group; *P<0.01, vs. control group.
Model group Yiqi Jianpi treatment group Yiqi Jianpi plus anticancer treatment group
Figure 2. Apoptosis detected by TUNEL method (3,3’-diaminobenzidine chromogenic assay, × 400).
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  The degree of cell apoptosis is an indicator of the 
efficacy of anti-tumor therapy. The present study found 
that there were a small number of apoptotic cells without 
drug intervention, while the number of apoptotic cells 
was increased after treatment. Yiqi Jianpi decoction alone 
could promote apoptosis, and Yiqi Jianpi plus anticancer 
decoction presents more pronounced effect[10-12].
  Both EGF and VEGF are the important factors that are 
conducive to the tumor growth. EGF is a stimulating factor 
of tumor growth, while VEGF functions to promote the 
growth of blood vessels and provide blood supply for tumor 
growth[13-15]. In this study, the expression of EGF and VEGF 
was decreased after drug treatment, thus weakening tumor 
growth[16]. Furthermore the inhibition effect was greatly 
improved after Yiqi Jianpi plus anticancer decoction, 
which was similar to the findings of cell apoptosis. 
Our experimental results indicate that Yiqi Jianpi plus 
anticancer herbs can promote the apoptosis of tumor cells 
and inhibit the contribution of EGF and VEGF, and its anti-
tumor effect is more pronounced than Yiqi Jianpi decoction 
alone.
  Tumor is prevalent to affect the functions of the spleen. 
Yiqi Jianpi treatment was shown to improve splenic function 
and Yiqi Jianpi plus anticancer treatment showed a stronger 
effect. Tumor also affects the growth of the spleen and 
may inhibit the expression of PKC in spleen, the inhibition 
effect could be reversed by Yiqi Jianpi plus anticancer 
treatment[17,18]. Yiqi Jianpi plus anticancer treatment is 
superior to Yiqi Jianpi treatment alone due to it cannot only 
inhibit tumor growth, but also decrease the expression of 
EGF and VEGF. Therefore the combined treatment achieves 
a double therapeutic efficacy: nourishing the spleen and 
anti-cancer[19]. In summary, we suggest the combination of 
Yiqi Jianpi plus anticancer herbs in the clinical practice, 
this remedy reflects the combination of “differential 
diagnosis of diseases” and “differential diagnosis of 
symptoms and signs” in traditional Chinese medicine 
treatment, and deserves further promotion.
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